RNA biomarkers of Parkinson's disease: developing tools for novel therapies.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Biomarkers in Medicine

• Publication date

  2008-01-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/17520363.2.1.41PMID 20477362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• SORL1 variants and risk of late-onset Alzheimer's disease.

  2008cited by this paper
• Reply: Role of DAT SPECT in the diagnostic work‐up of Parkinsonism

  2008cited by this paper
• ASSOCIATION BETWEEN GENETIC VARIANTS IN SORL1 AND AUTOPSY-CONFIRMED ALZHEIMER DISEASE

  2008cited by this paper
• The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort.

  2007cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease

  2007cited by this paper
• Trafficking Protein Suspected in Alzheimer's Disease

  2007cited by this paper
• Molecular biology. Trafficking protein suspected in Alzheimer's disease.

  2007cited by this paper
• Statistics in medicine--reporting of subgroup analyses in clinical trials.

  2007cited by this paper
• Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.

  2007cited by this paper
• Role of DAT‐SPECT in the diagnostic work up of Parkinsonism

  2007cited by this paper
• Why hasn't neuroprotection worked in Parkinson's disease?

  2007cited by this paper
• Molecular markers of early Parkinson's disease based on gene expression in blood

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

  2006cited by this paper
• The Lipoprotein Receptor LR11 Regulates Amyloid β Production and Amyloid Precursor Protein Traffic in Endosomal Compartments

  2006cited by this paper
• Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

  2006cited by this paper
• Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease

  2006cited by this paper
• Transcranial sonography in the early and differential diagnosis of Parkinson's disease.

  2006cited by this paper
• The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

  2006cited by this paper
• Huntington's Disease: A transcriptional report card from the peripheral blood: Can it measure disease progression in Huntington's disease?

  2006cited by this paper
• A unifying approach for surrogate marker validation based on Prentice's criteria

  2006cited by this paper
• Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

  2005cited by this paper
• Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces

  2005cited by this paper
• An integrative genomics approach to infer causal associations between gene expression and disease

  2005cited by this paper
• Nosology of Parkinson's disease: looking for the way out of a quagmire.

  2005cited by this paper
• Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.

  2005cited by this paper
• Biomarkers in Cancer Staging, Prognosis and Treatment Selection

  2005cited by this paper
• Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein.

  2005cited by this paper
• Prediction of cancer outcome with microarrays: a multiple random validation strategy.

  2005cited by this paper
• Simplifying Complex Neurodegenerative Diseases by Gene Chip Analysis

  2005cited by this paper
• α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication

  2004cited by this paper
• Yeast genetics targets lipids in Parkinson's disease.

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Loss of apolipoprotein E receptor LR11 in Alzheimer disease.

  2004cited by this paper
• Expression profiling — best practices for data generation and interpretation in clinical trials

  2004cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• Guidelines: Expression profiling — best practices for data generation and interpretation in clinical trials

  2004cited by this paper
• Rules of evidence for cancer molecular-marker discovery and validation

  2004cited by this paper
• Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease.

  2003cited by this paper
• Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment.

  2003cited by this paper
• Chipping away at the chip bias: RNA degradation in microarray analysis

  2003cited by this paper
• Novel risk markers and clinical practice.

  2003influential reference
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients

  2001influential reference
• Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease

  2001cited by this paper
• Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine

  2001cited by this paper
• Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease

  2001influential reference
• Modulation of in Vivo HSP70 Chaperone Activity by Hip and Bag-1*

  2001cited by this paper
• Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease.

  1999influential reference
• Increased expression of dopamine receptors on lymphocytes in Parkinson's disease

  1999influential reference
• Validation of a telephone questionnaire for Parkinson's disease.

  1998cited by this paper
• Differential expression of the parkin gene in the human brain and peripheral leukocytes.

  1998cited by this paper
• Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease

  1996influential reference
• Olfactory function in atypical parkinsonian syndromes

  1995cited by this paper
• Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle.

  1995cited by this paper
• Mitochondrial dysfunction in movement disorders

  1994cited by this paper
• Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome

  1994cited by this paper
• Population-based norms for the Mini-Mental State Examination by age and educational level.

  1993cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992influential reference
• Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease

  1992influential reference
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• AN ESSAY ON THE SHAKING PALSY

  1969cited by this paper

• Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives

  2025cites this paper
• Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study

  2019cites this paper
• Blood-Based Biomarkers for Alzheimer’s Disease and Related Dementias Potential two-step proteomic signature for Parkinson’s disease: Pilot analysis in the Harvard Biomarkers Study

  2019cites this paper
• Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

  2015cites this paper
• Identification of Neurexophilin 3 as a Novel Supportive Factor for Survival of Induced Pluripotent Stem Cell‐Derived Dopaminergic Progenitors

  2015cites this paper
• AWARD NUMBER: W81XWH-13-0115 TITLE: The Parkinson Transcriptome Project: Roadmap to Personalized Care PRINCIPAL INVESTIGATOR: Clemens R. Scherzer, MD RECIPIENT: The Brigham and Women’s Hospital, Inc

  2015cites this paper
• Tissue Engineering and Regenerative Medicine Identification of Neurexophilin 3 as a Novel Supportive Factor for Survival of Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors

  2015cites this paper
• Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study

  2014cites this paper
• Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease

  2014cites this paper
• SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3

  2014cites this paper
• Unrecognized vitamin D3 deficiency is common in Parkinson disease

  2013cites this paper
• Writ e Click: Editor ’ s Choice

  2013cites this paper
• Rapid microarray detection of DNA and proteins in microliter volumes with surface plasmon resonance imaging measurements.

  2011cites this paper
• Preclinical biomarkers of Parkinson disease.

  2011cites this paper
• Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

  2011cites this paper
• Exploiting the potential of molecular profiling in Parkinson’s disease: current practice and future probabilities

  2010cites this paper
• Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.

  2010cites this paper
• Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease

  2010influential citation
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cites this paper
• Chipping away at diagnostics for neurodegenerative diseases.

  2009influential citation
• Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration.

  2008cites this paper
• The search for biomarkers in Parkinson’s disease: a critical review

  2008cites this paper